UChicago Medicine Faculty Physicians
Mark A. Applebaum, MD
Mark A. Applebaum, MD
UChicago Medicine Faculty Physicians
Associate Professor of Pediatrics
Specialties
- Pediatric Hematology & Oncology (Pediatric Cancer)
Locations
- Chicago - Comer Children's Hospital
- About
- Specialties & Areas of Expertise
- Locations & Patient Information
- Education & Research
- Accepted Insurance
- External Professional Relationships
Mark Applebaum, MD, is an expert in pediatric cancers and blood diseases. He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors.
Dr. Applebaum is actively researching several aspects of neuroblastoma and pediatric solid tumors. His research harnesses the power of large genomic data sets in pediatric oncology to develop new "cancer-specific" targeted strategies that will ultimately improve outcomes while minimizing risk.
Dr. Applebaum also focuses his research on how the low-oxygen environment of tumors makes cancer cells more resistant to standard therapies. Identifying the genes and cellular pathways responsible for making cancer more aggressive in these conditions may ultimately open new avenues for novel therapeutic options.
Dr. Applebaum's research is supported in part by the University of Chicago Cancer Research Foundation Auxiliary Board. Additionally, he is the recipient of numerous awards, including the Brigid Leventhal Merit Award from the Conquer Cancer Foundation, the Bear Necessities Foundation Young Investigator Award, and the AACR-Aflac Inc. Scholar-in-Training award.
Dr. Applebaum is actively researching several aspects of neuroblastoma and pediatric solid tumors. His research harnesses the power of large genomic data sets in pediatric oncology to develop new "cancer-specific" targeted strategies that will ultimately improve outcomes while minimizing risk.
Dr. Applebaum also focuses his research on how the low-oxygen environment of tumors makes cancer cells more resistant to standard therapies. Identifying the genes and cellular pathways responsible for making cancer more aggressive in these conditions may ultimately open new avenues for novel therapeutic options.
Dr. Applebaum's research is supported in part by the University of Chicago Cancer Research Foundation Auxiliary Board. Additionally, he is the recipient of numerous awards, including the Brigid Leventhal Merit Award from the Conquer Cancer Foundation, the Bear Necessities Foundation Young Investigator Award, and the AACR-Aflac Inc. Scholar-in-Training award.
Areas of Expertise
- Pediatric Oncology
- Sarcomas
- Neuroblastoma
- Adolescent and Young Adult (AYA) Cancer Care
- Solid Tumors
Board Certifications
- Pediatric Hematology and Oncology
- Pediatrics
Practicing Since
- 2011
Languages Spoken
- English
Medical Education
- Northwestern University Feinberg School of Medicine
Residency
- University of California San Francisco Health
Fellowship
- University of Chicago Medicine
Memberships & Medical Societies
- American Association for Cancer Research
- American Society of Pediatric Hematology/Oncology
- American Society for Clinical Pharmacology and Therapeutics
- American Society of Clinical Oncology
News & Research
Insurance
- Aetna Better Health *see insurance page
- Aetna HMO (specialists only)
- Aetna Medicare Advantage HMO & PPO
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS Medicare Advantage HMO & PPO
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Choice HMO (specialists only)
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If you have questions regarding your insurance benefits at UChicago Medicine, please contact our financial counseling team at OPSFinancialCounseling@uchospitals.edu.
UChicago Medicine is committed to fostering a corporate culture of ethical behavior and integrity in all matters related to compliance with the laws and regulations that govern the delivery of healthcare. This aspiration is central to supporting patient care, research, and teaching at UChicago Medicine.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.